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Abstract
Background: Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB), affecting approximately
one third of the world’s population. Development of an adequate immune response will determine disease progression or
progress to chronic infection. Risk of developing TB among human immunodeficiency virus (HIV)-coinfected patients (HIV-TB)
is 20–30 times higher than those without HIV infection, and a synergistic interplay between these two pathogens accelerates
the decline in immunological functions. TB treatment in HIV-TB coinfected persons is challenging and it has a prolonged
duration, mainly due to the immune system failure to provide an adequate support for the therapy. Therefore, we aimed to
study the role of the hormone 7-oxo-dehydroepiandrosterone (7-OD) as a modulator of anti-tuberculosis immune responses
in the context of HIV-TB coinfection.
Methods: A cross-sectional study was conducted among HIV-TB patients and healthy donors (HD). We characterized the
ex vivo phenotype of CD4 + T cells and also evaluated in vitro antigen-specific responses by Mtb stimulation of peripheral
blood mononuclear cells (PBMCs) in the presence or absence of 7-OD. We assessed lymphoproliferative activity, cytokine
production and master transcription factor profiles.
Results: Our results show that HIV-TB patients were not able to generate successful anti-tubercular responses
in vitro compared to HD, as reduced IFN-γ/IL-10 and IFN-γ/IL-17A ratios were observed. Interestingly, treatment
with 7-OD enhanced Th1 responses by increasing Mtb-induced proliferation and the production of IFN-γ and
TNF-α over IL-10 levels. Additionally, in vitro Mtb stimulation augmented the frequency of cells with a regulatory
phenotype, while 7-OD reduced the proportion of these subsets and induced an increase in CD4 + T-bet+ (Th1)
subpopulation, which is associated with clinical data linked to an improved disease outcome.
Conclusions: We conclude that 7-OD modifies the cytokine balance and the phenotype of CD4 + T cells towards
a more favorable profile for mycobacteria control. These results provide new data to delineate novel treatment
approaches as co-adjuvant for the treatment of TB.
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Background
HIV and Mycobacterium tuberculosis (HIV-TB) coinfec-
tion represents a challenge for the study of its physiology,
since the presence of both pathogens is characterized by
persistent immune dysregulation and altered cytokine pro-
file. Although highly active antiretroviral therapy impedes
HIV replication and leads to increased CD4 + T cell num-
bers, Mtb-specific responses do not change substantially
over the first six months on antiretroviral therapy [1]. This
situation unravels the need for developing additional im-
munotherapies to protect from and control Mtb infection,
especially in HIV+ individuals. The identification of host
factors that promote disease progression or control may
lead to the discovery of new host-directed therapies
(HDT). In the context of HIV-TB coinfection, these treat-
ments should aim to enhance antigen-specific immune re-
sponses, reduce excess inflammation, preserve cell
function or improve the effectiveness of conventional
therapies. HDT could offer additional advantages for coin-
fected patients since they may reduce the length of treat-
ments, achieving better outcomes and/or decreasing the
chances of relapse or reinfection [2, 3].
Different cell subpopulations are involved in active
protection against M. tuberculosis (Mtb) infection. In
particular, CD4 + T cells restrict bacterial growth
through the production of cytokines that activate macro-
phages [4]. The variability in the quality and quantity of
cytokines produced at the onset of T cell activation de-
pends on the nature of the threat encountered [5]. IFN-γ
mediates macrophage activation through the induction
of phagocytosis, autophagy and antigenic presentation,
and contributes to the resistance and eradication of
intracellular pathogens [6, 7]. Additionally, TNF-α is es-
sential for the prevention of Mtb infection and mainten-
ance of latent TB infection [8, 9]. In contrast, IL-10 is a
regulatory cytokine that protects the host from excessive
inflammation and tissue damage and also inhibits im-
mune responses [10, 11]. Lastly, IL-17A contributes both
to the protection and the pathology of TB because it is
involved in the formation of mature granuloma [12], but
also it mediates the recruitment of neutrophils, which
are related to pathological damage of the lung [13].
To date, few studies have explored the effects of im-
munomodulatory compounds on the function of T cell
effectors in the context of TB, particularly during HIV
coinfection [14]. Our research group has published sev-
eral data on this subject, since we have studied the role
of DHEA in the context of HIV-TB coinfection for years
[15, 16]. In a recent report, we demonstrated the pres-
ence of a hormonal imbalance in HIV-TB patients, who
exhibited higher plasma levels of DHEA and its andros-
tenetriol (AET) and 7-oxo-DHEA (7-OD) metabolites.
Remarkably, we found that higher concentrations of 7-
OD positively correlated with absolute CD4 + T cell
counts and nadir CD4 + T cell values and also was asso-
ciated to lung-restricted TB infection [17].
Given the importance of CD4 + T cells over the control
of mycobacterial growth and the reported effect of DHEA
as an immune-modulating hormone, this work aimed to
study the effect of 7-OD on Mtb-induced cell prolifera-
tion, cytokine production and master transcription factors
expression in CD4 +T cells. Our results showed that Mtb
induced a response with a regulatory phenotype instead of
an effector response. On the contrary, 7-OD modified the
effect caused by Mtb-stimulation, inducing a Th1 type re-
sponse by increasing lymphoproliferation, the production
of IFN-γ and TNF-α over IL-10 levels and induced an
augment in CD4+ T-bet+ (i.e., Th1) subpopulation.
Therefore, we conclude that 7-OD modifies the balance of
cytokines and the profile of CD4 + T cells towards a more
favorable profile for mycobacteria control. These results
provide new data to delineate novel HDT approaches as
co-adjuvants for the treatment of TB.
Methods
Study population
This is a cross-sectional study. A total of 62 subjects
(Table 1) were recruited and classified into two groups:
1) chronic HIV-1+ infected individuals with active TB
(HIV-TB), who received none or less than two weeks of
anti-TB therapy at the moment of sample collection; 2)
healthy donors (HD), with no history of TB, HIV or sys-
temic infections. HIV-TB patients were evaluated at the
Hospital de Infecciosas “Dr. Francisco Javier Muñiz”,
Buenos Aires, Argentina. HIV and TB diagnosis was de-
termined following current guidelines. Some individuals
were on anti-retroviral treatment [18]. Peripheral blood
buffy-coats from HD were kindly provided by the
Hemotherapy Division of Sanatorio “Dr. Julio Mendez”,
Buenos Aires, Argentina. None of the subjects had meta-
bolic or endocrine disorders or received DHEA or gluco-
corticoids. The entire group of individuals had been
BCG (Bacillus Calmette-Guerin)-vaccinated at birth.
Table 1 Characteristics of the subjects enrolled in the study.
IQR: interquartile range. Mann-Whitney U test, **p < 0.01 and
****p < 0.001
Characteristic HIV-TB (n = 34) HD (n = 28)
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Antigens, mitogens and steroids
Pre-titrated Mycobacterium tuberculosis (Mtb) H37Rv
gamma-irradiated whole cells were obtained from BEI
Resources, NIAID, NIH (NR-14819); Phytohemmagluti-
nin (PHA) and DHEA were acquired from Sigma-
Aldrich, and 7-OD was purchased from Steraloids Inc.
Culture conditions
EDTA-anticoagulated blood samples were drawn during
morning hours. PBMCs were isolated by density gradient
centrifugation on Fycoll-Paque® and cultured in RPMI
medium (Sigma-Aldrich) supplemented with 10% fetal bo-
vine serum (PAA), 2mML-glutamine (Gibco BRL), 100 U/
mL penicillin (PAA) and 100mg/mL streptomycin (Gibco
BRL) at 37 °C in a humidified CO2 containing atmosphere.
PBMCs were stimulated with Mtb H37Rv gamma-
irradiated whole cells (10 μg/mL) and treated with DHEA
or 7-OD (at 1 × 10−9M, 1 × 10−8M, 1 × 10−7M and 1 ×
10−6M). We chose steroid concentrations that encompass
the spectra ranging from sub-physiological to pharmaco-
logical levels, according to our previous work [17].
Cell proliferation assay and cytokine production
PBMCs were plated at 2.5 × 105 cells/well in a U-bottom
96-well plate, as described above. Specific lymphoprolif-
eration was assessed by measuring [methyl-3H] thymi-
dine (GE Healthcare) incorporation. PBMCs were
cultured for 96 h, when [methyl-3H] thymidine (0.5 μCi
per well) was added and incubated for another 24-h
period. Cells were harvested by pouring them onto glass-
fiber filters (Whatman GF/A). Filters were placed into
vials containing liquid scintillation cocktail (2 ml/disc,
Optiphase Hisafe 2, PerkinElmer) to determine radiation
(counts per minute, CPM) in a liquid scintillation coun-
ter (LKB Wallac 1214 RackBeta). To assay cytokine pro-
duction, cell-free culture medium was obtained from
cultures assayed at 120 h. Supernatants were centrifuged
for 3 min at 13000 rpm, collected and stored at − 20 °C
until cytokine measurement was performed by ELISA,
according to the manufacturer’s instructions. IFN-γ, IL-
10, TNF-α (BD OptEIA™) and IL-17A (BioLegend) were
quantified.
Flow cytometry
Ex-vivo and in-vitro analysis were conducted. Recently
thawed or freshly isolated PBMCs were stained with
fluorochrome-conjugated antibodies (Abs) for ex vivo
study: PE-Cy7 anti-CD3, BV510 anti-CD4, FITC anti-
CD25, PE anti-FoxP3, Alexa Fluor 647 anti-ROR-γt, (BD
Biosciences) and PerCP/Cy5.5 anti-T-bet (BioLegend).
For the in vitro tests, PBMCs were first plated at 1 × 106
cells/ml in a 48-well plate, and incubated as described
above. Cells were treated with 7-OD at 1 × 10−6M or
DHEA at 1 × 10−7M. After 72 h, cells were harvested,
stained, and analyzed by flow cytometry. FoxP3 staining
protocol was used according to the manufacturer’s in-
structions (BD Biosciences). Negative control samples
were incubated with irrelevant isotype-matched mAbs in
parallel with experimental samples. Samples acquisition
and analysis were carried out on a FACSCanto flow cyt-
ometer using the BD FACSDiva software (BD Biosci-
ences). Data were analyzed with FlowJo Software
(Version 10.4, Tree Star) after gating on the lymphocyte
population in the FSC/SSC window and excluding cell
aggregates (doublets) by FSC-A/FSC-H and FSC-H/FSC-
W. Dead cells were excluded using Live/Dead viability
probe (Life Technologies). Gating strategy is shown in
Additional file 1: Figure S1. Boolean gating was used to
define individual non-overlapping functional subsets or
CD4 + T cells that expressed only two transcription fac-
tors. Frequencies were normalized to unstimulated con-
trol. Mean fluorescence intensity (MFI) was depicted as
the ratio of the geometric mean MFI of the marker of
interest over the MFI of the corresponding negative
population. MFI is expressed as median ± interquartile
range (IQR).
Statistical analyses
Statistical analyses were conducted using GraphPad
Prism 7 (GraphPad software Inc.). D’Agostino & Pearson
normality test was used to assess normal distribution.
Comparisons of the two groups for paired samples were
assessed by the paired t test or Wilcoxon matched-pairs
signed rank test, as appropriate. Alternatively, unpaired t
test or Mann-Whitney U test were used to evaluate un-
paired samples. Comparisons of three or more variables
were done using the Friedman test, followed by post-hoc
comparisons: Fisher’s LSD or Dunn’s test. Correlation
analyses were determined using the Spearman’s rank
test. p values < 0.05 were considered significant.
Results
Description of study cohorts
We initially analyzed memory responses to Mtb on
PBMCs, studying cell proliferation and cytokine produc-
tion (IFN-γ, IL-10, IL-17A and TNF-α). Cytokine produc-
tion ratio and correlation analyses were also performed
(Fig. 1). We observed that Mtb-induced lymphoprolifera-
tion in HIV-TB was higher than in HD (Fig. 1a). However,
compared to HIV-TB individuals, HD produced increased
levels of IFN-γ with respect to those of IL-10, IL-17A and
TNF-α (Fig. 1b), suggesting a predominant Th1-type re-
sponse. Alternatively, a positive association between the
secretion of IL-17A with IFN-γ and TNF-α was observed
in HIV-TB individuals (Fig. 1c). These data suggest that
HIV-TB patients are not able to generate an adequate re-
sponse for the containment of the bacteria, as a result of
the reduction in IFN-γ/IL-10 and IFN-γ/IL-17A ratios
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and the combined production of pro-inflammatory cyto-
kines (TNF-α and IL-17A) which unrestrained levels are
associated with immunopathology [19, 20].
7-oxo-DHEA boosts Mtb-specific lymphoproliferation
It is generally accepted that pathogen-specific T cells ex-
haustion prevents lymphoproliferation and the ability to
mediate effector functions during chronic infections [21].
In effect, the proliferative capacity of HIV-specific CD4 +
T cells is impaired in individuals with higher viral load
[22]. However, Mtb-specific CD4+ T cells from both of
both HIV-infected and uninfected individuals, preserve a
robust proliferative response [23]. Therefore, we studied
the effect of 7-OD and DHEA on Mtb-induced cell prolif-
eration. We observed that 7-OD significantly promoted
proliferative activity, with a differential outcome on cells
from HIV-TB individuals when compared with HD
(Fig. 2a, left upper panel). Otherwise, DHEA induced anti-
proliferative activity, in both HIV-TB individuals and HD
(Fig. 2a, left lower panel). We contrasted the modulatory
effect of 7-OD and DHEA at the highest dose (1 × 10−6M)
and found that 7-OD significantly promotes Mtb-specific
cell proliferation (Fig. 2b).
7-OD modifies Mtb-induced cytokine profile to a Th1-type
We aimed to study the effect of 7-OD over the cytokine
pattern (IFN-γ, IL-10, IL-17A and TNF-α) secreted by
Mtb-stimulated PBMCs. The results showed that 7-OD
significantly stimulated the production of IFN-γ and
TNF-α in both study groups (Fig. 2a, upper panel). No
modulation by 7-OD on IL-10 and IL-17A secretion was
observed in the HIV-TB group, while this hormone
downregulated the production of IL-10 (1 × 10− 9 M) and
stimulated the secretion of IL-17A in HD (Fig. 2a, upper
panel). On the other hand, DHEA increased the produc-
tion of IFN-γ and IL-10 in HD and HIV-TB (1 × 10− 7
M) (Fig. 2a, lower panel). DHEA also enhanced IL-17A
and TNF-α levels in HD at low doses (Fig. 2a, lower
panel), coinciding with its physiological plasma concen-
tration [17]. 7-OD (1 × 10−6M) was more effective than
DHEA in increasing the secretion of IFN-γ in HIV-TB
and TNF-α in both groups. In contrast, no differences
were observed between both hormone effects on the
production of IL-10 or IL-17A (Fig. 2b).
As Mtb modulate the production of cytokines in favor
of a regulatory response, an important feature of an ad-
juvant compound is the ability to promote a Th1 profile.
Thus, Mtb-induced cytokine ratio was analyzed. Re-
markably, 7-OD (1 × 10−6M) managed to significantly
upregulate IFN-γ/IL-10 and TNF-α/IL-10 ratios only in
patients (Fig. 3, upper panel). This effect was not
observed with DHEA (Fig. 3, lower panel), but both hor-
mones induced an increment of IFN-γ/IL-10 ratio in
HD. These data indicate that 7-OD was able to modulate
Mtb-specific cell proliferation and a Th1 type cytokine
profile during HIV-TB co-infection, by increasing the
levels of IFN-γ and TNF-α, without suppressing the ne-
cessary action of IL-10 and IL-17A, which would medi-
ate an optimal resistance to the mycobacteria [24].
Characterization of CD4 + Th subpopulations in HIV-TB
and HD individuals
Determination of the expression of transcription factors
(TF) FoxP3, ROR-γt and T-bet and of CD25 in PBMCs
from HIV-TB patients and HD was performed. In ex-vivo
analyses we found that HIV-TB patients presented higher
frequencies of CD4+ T-bet+ and CD4 + FoxP3 + T-bet+
cells, and exhibited lower numbers of CD4+ ROR-γt +
subpopulation compared to HD (Fig. 4a and b). Besides
conventional regulatory CD4 +T cells (i.e. Tregs, CD25 +
FoxP3+), the frequency of “unconventional” regulatory
CD4 +T cells (i.e. uTregs, CD25-FoxP3+) was also ana-
lyzed. This is a CD4 + FoxP3+ T cell population with un-
detectable levels of CD25 [25] that exerts an inhibitory
capacity supressing proliferation and cytokine production
from effector T cells [26]. We found that in HIV-TB pa-
tients uTregs were expanded, as reported elsewhere
(Fig. 5a and [25]). Moreover, within this cohort a larger
frequency of T-bet+ cells were observed in both Tregs
and uTregs populations (Fig. 5 b).
The balance Th1/Tregs may play an essential role in
clinical outcome
The balance among Th1, Th17, Tregs and uTregs phe-
notypes was analyzed. Unexpectedly, data revealed that
HIV-TB individuals presented a higher proportion of
Th1 cells over Tregs and Th17 populations, when com-
pared to HD (Fig. 6). We contrasted our findings with
clinical data from the patients enrolled. The frequency
(See figure on previous page.)
Fig. 1 In vitro responses to M. tuberculosis of PBMCs from HIV-TB and HD individuals. PBMCs from HD and HIV-TB individuals were stimulated with gamma-
irradiated Mtb (10μg/ml) for 5 days. Each graph depicts values from HIV-TB patients (black circles) and HD (open circles). Each symbol represents an individual
subject. a Mtb-induced proliferation and cytokine secretion. The Y axis shows cell proliferation or cytokine production. Values are relativized to unstimulated
cells. b Cytokine production profiles from HD and HIV-TB in response to Mtb. The Y axis indicates cytokine ratio. Error bars show mean± SEM. Unpaired t test or
Mann-Whitney U test, as appropriated *p <0.05, **p <0.01. c Correlation analysis among secretion of IFN-γ, IL-10, IL-17A and TNF-α from HIV-TB and HD groups.
Continuous lines represent linear regression curves, and dashed lines represent 95% confidence intervals. Spearman’s rank correlation coefficient (r), p value and
slope are indicated
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of CD25+, FoxP3+ or FoxP3 + T-bet+ cells was nega-
tively associated with CD4 + T cell count. The same re-
sults were observed for uTregs and Tregs, which also
correlated negatively with CD4/CD8 T cell ratio. CD4 +
FoxP3+ cells were associated with lower nadir CD4 + T
cell count and CD4/CD8 T cell ratio, whereas this subset
presented a positive correlation with viral load
(Table 2A). In addition, greater frequencies of CD4 +
FoxP3+ T cells were found in patients who were neither
on highly active antiretroviral therapy (HAART) nor TB
treatment and in those with extrapulmonary TB. Simi-
larly, higher proportions of Tregs were found in patients
who were not receiving HAART, and uTregs were
present to a greater extent in those individuals with dis-
seminated TB (Fig. 7a and b). These results suggest that
the expression of FoxP3 in CD4 + T cells may be associ-
ated with an unfavorable disease outcome in HIV-TB
patients. Conversely, T-bet expression could be related
to a favorable clinical outcome, since it was associated
with greater CD4 + T cell counts and nadir value (Table
2A) and with the development of a lung-restricted TB
instead of a disseminated infection. Moreover, uTregs
which express T-bet were present in greater frequency
in individuals with pulmonary TB (Fig. 7b). Finally, in
Fig. 2 7-OD and DHEA modulate Mtb-specific immune responses. PBMCs from HIV-TB and HD were stimulated with gamma-irradiated Mtb as
indicated in methods. a Effect of 7-OD and DHEA at different concentrations on Mtb-specific responses. The X axis indicates hormone concentrations. The Y
axis shows cell proliferation or cytokine production. Values are relativized to cells stimulated with Mtb (100%). The results are plotted for HD (open bars) and
HIV-TB patients (black bars). Error bars show mean± SEM. Statistical analyses were performed using absolute values. Unpaired t test or Mann-Whitney U test
*p <0.05, **p <0.01, ***p <0.005 and ****p <0.001. Numbers of individuals per group were from 8 to 18, according to sample availability. b Comparison of the
immunomodulatory capacity of 7-OD and DHEA at 1 × 10−6M on PBMCs stimulated with Mtb. Values are relativized to the cells stimulated only with antigen
(100%). The results are plotted for HIV-TB patients (black circles) and HD (open circles). Each symbol represents an individual subject. The statistical analysis was
performed using absolute values. Unpaired t test or Mann-Whitney U test, as appropriated *p <0.05, **p <0.01, and ***p <0.005. a and b To estimate the
immunomodulatory effect of steroids, the response of Mtb-stimulated cells was defined as 100%. The calculation was: Modulation (%) = (Mtb-stimulated and
hormone treated - unstimulated) / (Mtb-stimulated - unstimulated) × 100
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individuals who had not received TB treatment, higher
frequencies of CD4 + T cells expressing CD25 or ROR-
γt were found (Fig. 7c).
The association between clinical data and the ratio
among Th1, Th17, Tregs, uTregs and CD4 + Foxp3+ T
subsets was also analyzed. A higher Th1/FoxP3 ratio was
related with greater CD4 + T cell counts and nadir
values. Furthermore, Th1/FoxP3, Th1/Tregs and Th1/
uTregs ratios were increased in patients on HAART and
diagnosed with lung-restricted TB infection (Fig. 8a and
b). In addition, a greater Th1/Tregs balance positively
correlated with total and nadir CD4 + T cell counts,
CD4/CD8 T cell ratio and had negative association with
viral load (Table 3). On the other hand, Th17/FoxP3 ra-
tio positively correlated with greater values of total and
nadir CD4 + T cell counts and with pulmonary TB
(Table 3). Moreover, Th17/Treg ratio was associated
with higher CD4 + T cell counts and individuals on
Fig. 3 Ratios of in vitro Mtb-specific cytokine production are modified by 7-OD and DHEA. PBMCs from HIV-TB individuals (black circles) and HD
(open circles) were stimulated with gamma-irradiated Mtb in the presence/absence of hormones, as specified in methods. The Y axis indicates
cytokine production ratio in response to Mtb and its modulation by (a) 7-OD or (b) DHEA, both at 1 × 10−6M. Each symbol represents an individual
subject. The statistical analysis was performed using absolute values. Paired t test or Wilcoxon matched-pairs signed rank test, as appropriated *p < 0.05
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HAART. Lastly, Th17/uTregs ratio was greater in HIV-
TB patients with pulmonary TB compared with those
with a disseminated disease. No associations were found
between the balance of CD4+ Th subpopulations and
anti-TB treatment, probably due to the low number of
untreated patients at the time of recruitment (Fig. 8b).
Mtb alters CD4+ T cell phenotype in vitro
The capacity of Mtb to modulate the profile of CD4+ T
cell subpopulations in vitro was analyzed. Mtb stimula-
tion increased the frequency of CD4 + CD25+ and
CD4 + FoxP3 cells, but it did not modify the proportion
of ROR-γt and T-bet in HIV-TB patients (Fig. 9 a). The
same pattern was detected in HD, with the exception of
greater proportion of CD4 + T-bet+ (Additional file 2:
Figure S2 A). Besides, Mtb increased the frequency of
CD4 + T cells that expressed two transcription factors
simultaneously in both HIV-TB and HD (Fig. 9 b and
Additional file 2: Figure S2 B). In addition, Mtb-stimula-
tion induced a higher expression of CD25 on a per cell
basis and downregulated ROR-γt expression (Add-
itional file 5: Table S1) in both study cohorts.
Mtb stimulation also augmented the frequency of
Tregs and uTregs in both HIV-TB individuals and HD
(Fig. 9c and Additional file 2: Figure S2 C). However,
there were no changes in the proportion of cells that
expressed ROR-γt and T-bet within these populations
(data not shown). Finally, we contrasted the changes in-
duced by Mtb between groups and observed significant
differences in the frequency of CD4+ T-bet+ and CD4 +
FoxP3 + ROR-γt + cells, finding a greater proportion of
these populations in HD (Fig. 10).
7-OD modifies Mtb-specific immune response in the
context of HIV and Mtb infection
As 7-OD modulated Mtb-specific lymphoproliferation
and cytokine production, we aimed to study its effect on
CD4+ Th cell phenotype. Remarkably, 7-OD increased
the frequency of CD4+ T-bet and reduced the frequency
of CD4 + FoxP3 + T-bet+ in HIV-TB patients. Further-
more, both 7-OD and DHEA diminished the percentage
of cells expressing CD25+ or FoxP3+, and restored the
effect of Mtb on CD4+ lymphocytes (Fig. 11a). Within
the cohort of HD, while 7OD raised the frequency of
CD4+ T-bet+ cells, DHEA expanded the CD4 + FoxP3 +
RORγ-t + population and declined the number of cells
that co-expressed FoxP3+ and T-bet after antigen (Ag)-
exposure (Additional file 3: Figure 3A).
Concerning regulatory populations, treatment with
both 7-OD and DHEA decreased the frequency of
uTregs without modifying Tregs in HIV-TB individuals
(Fig. 11b), while both Tregs and uTregs in HD declined
in the presence of DHEA (Additional file 3 Fig. S3B). Be-
sides, DHEA enhanced the expression of T-bet in Tregs
and uTregs in the group of HIV-TB (Fig. 11b), while 7-
OD augmented the proportion of uTregs expressing
ROR-γt in HIV-TB and HD (Fig. 11b and Additional file
3: Figure S3B). Together, these data suggest that both 7-
OD and DHEA are able to modify the effect of Mtb on
CD4+ Th cell phenotype, but only 7-OD modulates it
toward a Th1-like profile.
The expression of each TF was also analyzed on a per
cell basis. Our data reveals that 7-OD enhanced the
levels of T-bet in CD4 + T cells from HIV-TB (Add-
itional file 5: Table S1). However, this did not occur in
HD individuals (data not shown). In conclusion, 7-OD
not only modified the percentage of cells expressing dif-
ferent TF, but also changed their levels of expression in
HIV-TB patients, partially restoring the effect of Mtb on
these populations.
The balance among different CD4 + T cell subpopulations
is disturbed by Mtb and modified by 7-OD and DHEA
In order to study the changes that Mtb induced on the
CD4 + T cell phenotype, TF ratio among different sub-
populations was analyzed. The stimulation of PBMCs
with Mtb reduced Th1/FoxP3, Th1/Tregs and Th1/
FoxP3 + T-bet+ ratios in both HD and HIV-TB cohorts
(Fig. 12a and Additional file 4: Figure S4A). Additionally,
in co-infected individuals, Th1/uTregs ratio was also de-
creased (Fig. 12a). No variations in Th1/Th17 and Th17/
regulatory ratios were observed in coinfected patients
(Fig. 12a), but we found that Mtb reduced Th17/FoxP3
balance in HD (Additional file 4: Fig. S4A).
We wondered if the unbalance in CD4+ Th cells elic-
ited by Mtb may be restored by in vitro treatment with
7-OD and/or DHEA. Remarkably, 7-OD induced an in-
crease in Th1 population over CD4+ FoxP3+, Tregs,
uTregs and FoxP3 + T-bet+ T cells in HIV-TB patients.
Additionally, DHEA also raised Th1/uTregs ratio in co-
infected individuals (Fig. 12b). On the other hand, within
the group of HD, 7-OD augmented Th1/FoxP3 and
Th1/Tregs ratios while DHEA had the same effect on
Th1/uTregs balance. Lastly, in the same cohort, DHEA
diminished Th1/Th17 ratio (Additional file 4: Figure
S4B). These data demonstrate that CD4 + T cells develop
(See figure on previous page.)
Fig. 4 Phenotype of CD4 + T cells from HD and HIV-TB. Recently thawed or freshly isolated PBMCs were stained and analyzed by flow cytometry.
Figure shows the percentage of CD4+ cells that express (a) FoxP3, T-bet or ROR-γt and (b) the co-expression of transcription factors using a
Boolean gating strategy. Representative flow cytometry examples are shown. The results are plotted for HD (open circles) and HIV-TB patients
(black circles). Each symbol represents an individual subject. Unpaired t test or Mann-Whitney U test, as appropriated *p < 0.05
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a specific immunity toward certain Th phenotype
through interactions with Mtb antigens, associated with
a regulatory pathway. Nevertheless, this immunosup-
pressive milieu was overturn by the influence of 7-OD,
which allowed the appropriate expansion of Th1 CD4 +
T cells, an important subset for disease resolution.
Discussion
HIV deleterious effects over TB infection are diverse, in-
volving the specific and lasting effect on Mtb-specific
immunity. The type of individual immune response will
determine disease progression or its development into a
chronic stage. Novel host-directed therapies (HDT) that
potentiate immunity could be discovered by studying
and identifying factors that lead to disease progression
or resolution. Therefore, the aim of this research was to
scrutinize the role of 7-OD on lymphocyte phenotype
and function during HIV-TB coinfection.
The ability to proliferate and differentiate into
cytokine-producing effector cells is an important charac-
teristic to pathogen control [27]. We found that patients
exhibited higher proliferative response compared to HD,
which can be explained by Mtb-specific T cell clones in
HIV-TB. HD responded to Ag-stimulation owing to pre-
vious BCG immunization or exposure to environmental
mycobacteria [28]. Previous reports also demonstrated
HIV-TB subjects maintain Mtb-specific proliferative
capacity, regardless of the low absolute CD4 + T cells
counts and the rapid depletion of Mtb-specific responses
after HIV infection [23, 29]. The current results show
that 7-OD induces an augmented lymphoproliferation,
while DHEA seems to suppress this activity. The lack of
modulation by DHEA was reported formerly in PBMCs
from TB patients [30]. Thus, our data indicate that con-
centrations of 7-OD superior to a physiologic range may
enhance Mtb-specific immune lymphoproliferative re-
sponse during HIV-TB coinfection.
Because of inter-individual variability, the use of cyto-
kine ratios rather than single cytokine measurements
would improve the study of immune responses. We
demonstrate that the production of the protective cyto-
kines IFN-γ and TNF-α is accompanied by the secretion
of IL-17A in confected individuals, suggesting a height-
ened cytokine inflammatory response. Interestingly,
HIV-TB individuals displayed reduced IFN-γ/IL-10,
IFN-γ/IL-17A and IFN-γ/TNF-α ratios compared to
HD. Other authors described a lower ratio of IFN-γ/IL-
10 in drug-resistant patients during TB-Immune Recon-
stitution Inflammatory Syndrome (IRIS), which corre-
lated with higher bacterial load [31]. In systemic lupus
erythematosus, it was reported that TNF-α could be pro-
tective, since its levels and TNF-α/IL-10 ratio were lower
in patients with active disease [32]. Furthermore, it was
found higher IFN-γ/TNF-α ratio in household contacts
(See figure on previous page.)
Fig. 5 Analysis of Treg and uTreg subsets within CD4+ T cells from HIV-TB patients and HD. Recently thawed or freshly isolated PBMCs were stained and
analyzed by flow cytometry. Figure shows the percentage of (a) CD4+ regulatory T cells (Tregs, CD25 + FoxP3+) and CD4+ unconventional regulatory T cells
(uTregs, CD25-FoxP3+) and (b) the co-expression of the transcription factors ROR-γt or T-bet within each population. The results are plotted for HD (open
circles) and HIV-TB patients (black circles). Each symbol represents an individual subject. Unpaired t test or Mann-Whitney U test, as appropriated *p < 0.05.
Representative flow cytometry examples are shown
Fig. 6 Changes in the balance between Th1, Tregs, uTregs and Th17 cells in patients with HIV-TB compared with HD. Recently thawed or freshly
isolated PBMCs were stained and analyzed by flow cytometry. Figure shows CD4 + T cell subset ratios. The results are plotted for HD (open circles) and
HIV-TB patients (black circles). Each symbol represents an individual subject. Unpaired t test or Mann-Whitney U, as appropriated *p < 0.05
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when compared to TB patients [33]. Remarkably, 7-OD
modified the impaired immune response against Mtb in
HIV-TB patients, with an augment in IFN-γ and TNF-α
secretion as well as an increment in IFN-γ/IL-10 and
TNF-α/IL-10 ratios. The effect of 7-OD in lymphoprolif-
eration and cytokine production in response to Mtb may
induce a protective Th1-like response in the context of
HIV-TB coinfection.
Then, we investigated CD4 + T cell phenotype of
PBMCs from HD and patients ex vivo. We observed that
HIV-TB individuals exhibited lower frequencies of CD4+
ROR-γt + T cells but greater proportions of CD4 + T-
bet+, CD4 + FoxP3 + T-bet+ and uTregs (CD4 +CD25-
FoxP3+). We found that higher proportions of the CD4 +
ROR-γt + subset were associated with those patients on
TB treatment vs. untreated individuals. Although its role
in human pathology has not yet been fully elucidated, a
mouse model revealed that cells expressing ROR-γt + were
critical to the induction of an Mtb-specific memory re-
sponse [34, 35]. Additionally, we observed larger frequen-
cies of the CD4 + T-bet+ population that were associated
with better clinical status and propitious disease outcome.
These results are in line with the role of T-bet as the mas-
ter regulator of Th1 cells, involved in the protective and
inflammatory responses during Mtb infection [7, 24].
Conversely, we associated both uTregs and CD4 +
FoxP3 + T-bet+ T cells with an unfavorable outcome. Fur-
thermore, uTregs were found in greater proportion in
Table 2 Correlation analysis between the transcriptional profile of Mtb-Specific CD4 + T cells and clinical data from HIV-TB patients.
Table shows the results of CD4 + T cells expressing (A) CD25, FoxP3, ROR-γt or T-bet and the co-expression of FoxP3, ROR-γt and T-
bet. Additionally, (B) Tregs (CD25 + FoxP3+) and uTregs (CD25-FoxP3+) subsets and the co-expression of the transcription factors
ROR-γt or T-bet within each subpopulation were analyzed. A comparison of the percentage of different CD4+ Th cells was
performed with total and nadir CD4 + T cell counts, CD4/CD8 ratio and viral load. Number of values (n), Spearman’s rank correlation
coefficient (r), and p value are indicated
Clinical parameter FoxP3+ ROR-γt+ T-bet+ CD25+ FoxP3+ ROR-γt+ ROR-γt + T-bet+ FoxP3+ T-bet+
A
CD4 + T cell count (cell/ml) n = 14 n = 14 n = 15 n = 15 n = 14 n = 14 n = 15
r = −0.66 r = 0.14 r = 0.48 r = − 0.45 r = 0.29 r = 0.37 r = − 0.49
p = 0.0035 p = 0.31 p = 0.041 p = 0.045 p = 0.16 p = 0.19 p = 0.029
Nadir CD4 T cell count (cell/ml) n = 15 n = 14 n = 14 n = 15 n = 14 n = 14 n = 15
r = −0.65 r = 0.55 r = 0.65 r = − 0.41 r = 0.091 r = 0.61 r = − 0.29
p = 0.021 p = 0.45 p = 0.014 p = 0.22 p = 0.40 p = 0.033 p = 0.28
CD4/CD8 T cell ratio n = 15 n = 14 n = 15 n = 15 n = 14 n = 14 n = 15
r = −0.55 r = − 0.12 r = 0.23 r = − 0.27 r = − 0.034 r = 0.13 r = − 0.17
p = 0.018 p = 0.35 p = 0.21 p = 0.16 p = 0.49 p = 0.63 p = 0.27
Viral load (copies/ml) n = 15 n = 14 n = 15 n = 15 n = 14 n = 14 n = 15
r = 0.56 r = 0.25 r = − 0.14 r = 0.41 r = 0.15 r = 0.013 r = 0.071
p = 0.015 p = 0.19 p = 0.32 p = 0.13 p = 0.30 p = 0.97 p = 0.80
B
Clinical parameter Tregs Tregs ROR-γt+ Tregs
T-bet+
uTregs uTregs ROR-γt+ uTregs
T-bet+
CD4 + T cell count (cell/ml) n = 15 n = 14 n = 15 n = 15 n = 14 n = 15
r = −0.71 r = 0.33 r = − 0.17 r = − 0.48 r = 0.059 r = − 0.22
p = 0.015 p = 0.25 p = 0.54 p = 0.036 p = 0.84 p = 0.42
Nadir CD4 T cell count (cell/ml) n = 15 n = 15 n = 14 n = 14 n = 14 n = 14
r = − 0.43 r = 0.16 r = − 0.19 r = − 0.29 r = − 0.27 r = − 0.22
p = 0.090 p = 0.66 p = 0.58 p = 0.19 p = 0.44 p = 0.49
CD4/CD8 T cell ratio n = 15 n = 14 n = 15 n = 15 n = 14 n = 15
r = − 0.53 r = 0 r = − 0.17 r = − 0.27 r = − 0.059 r = − 0.16
p = 0.022 p = 0.50 p = 0.55 p = 0.15 p = 0.84 p = 0.55
Viral Load (copies/ml) n = 14 n = 14 n = 14 n = 14 n = 14 n = 14
r = 0.42 r = 0.0083 r = − 0.23 r = 0.17 r = − 0.033 r = − 0.14
p = 0.14 r = 0.98 p = 0.43 p = 0.27 p = 0.92 p = 0.63
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Fig. 7 Analisys of different CD4 + T cell subsets and different clinical parameters from HIV-TB patients. CD4 + T cell phenotype from HIV-TB were
associated with clinical data: (a) patients on HAART (+) vs. untreated patients (−) at the moment of sample collection, (b) diagnosis of pulmonary (P) or
extrapulmonary (E) TB, and (c) individuals on anti-tuberculous treatment -less than two weeks- (+) vs. untreated patients (−) at the moment of sample
collection. Each symbol represents an individual subject. Unpaired t test or Mann-Whitney U test, as appropriated *p < 0.05 and **p < 0.01
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those individuals with disseminated TB. A recent study re-
vealed that a cohort of HIV+ individuals with latent TB
exhibited a reduction in CD4 + FoxP3 + T-bet+ subset,
which correlated inversely with viral load [27]. Our results
indicated that this population is associated with an un-
favorable result, but differences may be due to a different
recruited cohort and that the authors studied Ki67+ cells
CD4 + T cells [36]. Otherwise, our previous results ob-
served an increased frequency of uTregs during HIV-TB
disease [25] and described that this population exerts
regulatory functions, in spite of an altered surface expres-
sion of markers and differences in cytokine production
[37]. In line with this, lower Th1/uTregs ratio was ob-
served in those patients who were not on HAART and
who developed a disseminated TB infection. Our data
therefore suggest that the expansion of uTregs population
may be involved in the pathogenesis of TB.
Ex vivo analysis also showed that Th1/FoxP3 and Th1/
Tregs ratios were higher in HIV-TB cohort. However,
superior proportion of Th1 cells as well as Th1/FoxP3
and Th1/Tregs ratios positively correlated with total and
nadir CD4 + T cell counts and with those individuals
who presented pulmonary instead of disseminated TB.
Similarly, higher proportions of Th1 population over
CD4 + FoxP3+ and Tregs were associated with patients
on HAART, while Th1/Tregs were related with a higher
CD4/CD8 T cell ratio and negatively correlated with
viral load. We hypothesize that the balance between Th1
and FoxP3+ or Tregs cells may have a critical role in the
immune response during HIV-TB, as these parameters
are related with clinical data associated with disease con-
sequences, as we discussed in a previous report [17].
Afterwards, we analyzed in vitro Mtb stimulation on
CD4+ Th phenotype. Ag-stimulation raised the propor-
tion of CD4 + FoxP3+, Tregs and uTregs in HIV-TB pa-
tients. The proportion of Treg in pleural fluid inversely
correlated with Mtb-specific immunity at the site of in-
fection [38]. Higher frequencies of Treg suggest that
these cells participate in immunosuppression observed
in individuals with more severe active disease [38, 39]
and persist beyond completion of anti-TB therapy [40].
Furthermore, in HIV-TB patients we observed a signifi-
cant drop in frequencies of uTregs in response to TB
treatment (unpublished data). While a Th1 response or-
chestrated immunity to intracellular pathogens, CD4 + T
cells with a regulatory phenotype were associated with
long-term adverse outcomes [27, 41]. Therefore, the bal-
ance between effector and suppressive immune re-
sponses is essential to control Mtb infection.
Hormone effect on CD4 + T cell lineage in a HIV-TB
milieu was studied. Of note, 7-OD reduced the fre-
quency of CD4 + T cells with a regulatory function and
led to an augment in the frequency of CD4 + T-bet+
subset. This hormone also increased the proportion of
(See figure on previous page.)
Fig. 8 Association between the CD4 + T cell subsets ratio with clinical parameters in HIV-TB patients. Phenotype of CD4 + T cell subset ratios from
HIV-TB were correlated with clinical data: (a) patients on HAART (+) vs. untreated patients (−) at the moment of sample collection, (b) diagnosis
of pulmonary (P) or extrapulmonary (E) TB, and (c) individuals on anti-tuberculous treatment -less than two weeks- (+) vs. untreated patients (−)
at the moment of sample collection. Each symbol represents an individual subject. Unpaired t test or Mann-Whitney U test, as appropriated *p <
0.05 and **p < 0.01
Table 3 Correlation between clinical parameters and ratios of different CD4+ subpopulations. A comparison of different CD4+
subsets ratios was performed with total and nadir CD4 + T cell counts, CD4/CD8 ratio and viral load. Number of values (n), Spearman’s















CD4 + T cell count (cell/ml) n = 15 n = 14 n = 15 n = 14 n = 13 n = 13 n = 13
r = 0.59 r = 0.70 r = 0.55 r = 0.055 r = 0.57 r = 0.65 r = 0.24
p = 0.011 p = 0.0026 p = 0.018 p = 0.43 p = 0.024 p = 0.18 p = 0.44
Nadir CD4 T cell count (cell/ml) n = 15 n = 14 n = 15 n = 14 n = 14 n = 14 n = 14
r = 0.60 r = 0.66 r = 0.36 r = 0.37 r = 0.56 r = 0.48 r = 0.20
p = 0.025 p = 0.018 p = 0.14 p = 0.15 p = 0.048 p = 0.16 p = 0.58
CD4/CD8 T cell ratio n = 15 n = 14 n = 15 n = 14 n = 13 n = 13 n = 13
r = 0.25 r = 0.49 r = 0.20 r = 0.23 r = 0.22 r = 0.33 r = 0.14
p = 0.19 p = 0.036 p = 0.23 p = 0.21 p = 0.23 p = 0.26 p = 0.65
Viral Load (copies/ml) n = 15 n = 15 n = 15 n = 14 n = 14 n = 14 n = 14
r = −0.37 r = −0.51 r = − 0.38 r = − 0.34 r = − 0.25 r = − 0.28 r = 0.19
p = 0.087 p = 0.027 p = 0.081 p = 0.12 p = 0.19 p = 0.33 p = 0.52
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cells expressing ROR-γt within uTregs. Although we
could not find any association between the former popu-
lation and clinical data, studies performed in mice and
humans demonstrated that Tregs can be reprogrammed
into IL-17 + Foxp3+ T cells, which are believed to con-
trol pathological inflammation, potentially antagonizing
pro-inflammatory IL-17-producing cells [42].
There may be an association between a transcription factor
or marker expression levels and a functional capacity [43,
44]. The assessment of MFI revealed that Mtb-stimulation
induced higher levels of CD25 and downregulated ROR-γt
expression on total CD4+T cells. A research work found
that ROR-γt expression was diminished in tuberculin skin
test (TST) positive individuals, suggesting that lack of Th17
cells predisposes to latent infection [45]. At the same time,
an augment in the expression of CD25 was associated with a
regulatory phenotype in the context of TB [40, 46] and HIV
[47]. Our data demonstrated that 7-OD modified the effect
of Mtb on CD4+ lymphocytes by augmenting the expression
of ROR-γt and T-bet, potentially enhancing their immune
functions. In summary, Mtb boosts the frequency of CD4+
T cells that expresses FoxP3 and modified the expression of
CD25 and ROR-γt on a per cell basis. However, 7-OD could
reverse this effect by changing the frequency of effector Th1
cells and regulatory CD4+T cells and the levels of transcrip-
tion factors, improving thus its functionality.
It is known that Mtb infection induces highly poly-
functional responses [48], stimulating the co-expression
of FoxP3, T-bet and/or ROR-γt in CD4 + T lymphocytes
and that HIV infection alters the transcriptional profiles
of these cells [27]. Our findings showed that exposure to
Mtb antigens promoted the expansion of those popula-
tions in HD and coinfected patients. Cells producing
both IL-17 and IL-10 were considered to play a protect-
ive regulatory homeostatic role, while CD4+ Th17 popu-
lation co-secreting IFN-γ were associated with pathology
[49]. CD4 + FoxP3 + ROR-γt + lymphocytes have the
capacity to produce IL-17 and exhibit suppressive func-
tions via a cell-cell contact mechanism and the secretion
of IL-10 [42, 50]. In subjects with latent TB significantly
higher frequencies of regulatory IL10 + Th17 were found
compared to subjects with extrapulmonary TB when
PBMCs were stimulated with latency antigens. Con-
versely, the response to ESAT6/CFP10 was predomin-
antly managed by IFN-γ + Th17 T cells [49]. In this
report, we found that higher frequencies of ROR-γt + T-
bet+ CD4 + T cells in the cohort of HIV-TB patients
were associated with greater levels of nadir CD4 + T cell
(See figure on previous page.)
Fig. 9 Mtb induces changes in CD4+ T-cell phenotype from HIV-TB patients. Recently thawed or freshly isolated PBMCs from HIV-TB individuals
were stimulated with an antigen of Mtb, stained and analyzed by flow cytometry, as indicated in methods. Figure shows the percentage of CD4 + T
cells that express (a) FoxP3, T-bet, ROR-γt or CD25 and (b) the co-expression of transcription factors using a Boolean gating strategy. c Tregs (CD4+
CD25+ FoxP3+) and uTregs (CD4+ CD25- FoxP3+) subsets were also analyzed. Representative flow cytometry examples are shown. Each symbol
represents an individual subject. Unpaired t test or Mann-Whitney U test, as appropriated *p < 0.05, **p < 0.01 and ***p < 0.005
Fig. 10 Comparative CD4 + T cell response from HD and HIV-TB cohorts to Mtb. Recently thawed or freshly isolated PBMCs from HD and HIV-TB
individuals were stimulated with an antigen of Mtb, stained and analyzed by flow cytometry, as indicated in methods. The results are plotted for
HIV-TB (black circles) patients and HD (open circles). Each symbol represents an individual subject. The figure shows the percentage of CD4 + T
cells that express (a) FoxP3, T-bet, ROR-γt or CD25 and (b) the co-expression of transcription factors using a Boolean gating strategy. (c) Tregs
(CD4 + CD25 + FoxP3+) and uTregs (CD4 + CD25-FoxP3+) subsets and the co-expression of ROR-γt or T-bet within each subpopulation were
analyzed. Values are relativized to unstimulated cells. Error bars show mean ± SEM. Unpaired t test or Mann-Whitney U test, as appropriated
*p < 0.05 and **p < 0.01
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counts, although we could not find any effects after the
addition of hormones.
Recent studies demonstrated that CD4 + T cells ex-
pressing both, T-bet and FoxP3, exert regulatory rather
than pro-inflammatory functions. T-bet is required for
the expansion of these immunosuppressive cells to limit
Th1-mediated immune responses [51, 52]. We hypothe-
sized this subset might be involved in pathogen-specific
loss of host resistance. In this report we found that Mtb
augmented the proportion of CD4 + FoxP3 + T-bet+
cells, which was negatively associated with peripheral
CD4 + T cell numbers, whereas treatment with 7-OD
reduced the frequency of this subpopulation. Thus, the
results indicate that 7-OD promotes an immunoprotec-
tive profile, not only by increasing the number of Th1
cells and the expression of T-bet per cell, but also by de-
creasing specific Th1 inhibitory (i.e., CD4 + FoxP3 + T-
bet+ cells) responses.
Finally, we examined Th profile ratios inasmuch as the
balance between Th1 and regulatory pathways might de-
fine resolution of Mtb infection and disease outcome.
The role of Th cells has been investigated from active
disease to post-treatment status [41, 53]. One report
showed a reduction in Th1 cells in active-TB patients,
followed by an increase in these cells after clinical cure
[54]. Another report informed about an increase in the
percentage of Mtb-specific Tregs during active TB, with
lesser Th1/Treg and Th17/Treg ratios [54]. We observed
that Mtb stimulation increased the numbers of lympho-
cytes with a regulatory phenotype over Th1 CD4 + T
cells (lower Th1/FoxP3, Th1/Tregs, Th1/uTregs and
Th1/FoxP3 + T-bet+ ratios in patients). Other authors
suggested that it would be useful for monitoring pro-
gression of infection to focus on the study of the relative
balance between Th1/regulatory cells rather than on the
analysis of a specific cell subset [55]. We discovered 7-
OD and DHEA augmented Th1/uTregs ratio, but only
7-OD could reverse the effect of Mtb in terms of the bal-
ance of Th1/FoxP3, Th1/Tregs and Th1/FoxP3 + T-bet+
in HIV-TB individuals.
There is little prior information about the mechanism of
action of 7-OD on eukaryotic cells, but no data about its
effects on CD4+ T lymphocytes. It was reported that 7-
OD modulated cell metabolic activity by rising the levels
of mitochondrial glycerol-3-phosphate dehydrogenase
(GPD2) and malic enzyme in rats [56, 57]. Also, it was
demonstrated that GPD2 participates in glycolysis, gluco-
neogenesis, glycerol and triacylglycerol metabolism [58].
Moreover, GPD2 is an alternative source of mitochondrial
reactive oxygen species (mROS) [59], which are required
for CD4+ T cell activation and expansion [60]. It was
shown that reduction of GPD2 levels leads to decrease in
ROS-mediated oxidative signal and the induction of NF-
κB-dependent gene expression [59]. Likewise, NF-κB acti-
vation in T cells promoted clonal expansion during the
Th1 response, Th1 differentiation and production of IL-2,
IFN-γ and TNF-α [61, 62]. We therefore hypothesize that
7-OD stimulates GPD2 abundance and/or activity condu-
cing to ROS production, NF-κB genes expression and the
differentiation of CD4+ T cells to a Th1 subset. However,
further research is needed to corroborate this hypothesis,
given the unexplored nature of the effects of 7-OD on this
cell type. Taking into account our results and the informa-
tion from other authors, we can infer that both mecha-
nisms are working in patients, since the effect at the
cellular as well as the systemic level are operating. Thus,
we hypothesize that 7-OD-induced modulation of 11β-
HSD1 activity [63] from peripheral tissues could regulate
cortisol levels and, in parallel, 7-OD stimulation of GPD2
on CD4+ T cells could impact on its metabolism, enhan-
cing T cell activation, proliferation and Th1 differenti-
ation. The differential effect of 7-OD in patients and HD
may be caused by a higher number of Mtb-specific clones
in HIV-TB individuals and/or a different metabolic state
in CD4+ T cells that make them suitable to be modulated
by 7-OD.
Conclusions
In summary, our results suggest that Mtb modulate
CD4 + T cell phenotype and functionality in HIV-TB pa-
tients. Besides, we described the effect of 7-OD on lym-
phoproliferation, cytokine production profile and CD4+
Th cell subpopulations in vitro. Firstly, 7-OD augmented
the Mtb-induced proliferative capacity of PBMCs from
the study population. Secondly, this hormone enhanced
IFN-γ and TNF-α production, without suppressing the
necessary action of IL-10 and IL-17A. Moreover, 7-OD
promoted the secretion of IFN-γ and TNF-α over IL-10,
therefore modifying the cytokine balance towards a more
favorable profile for Mtb control. Third, while Mtb
(See figure on previous page.)
Fig. 11 Mtb-specific response in HIV-TB patients is modulated differentially by 7-OD and DHEA. Recently thawed or freshly isolated PBMCs from
HIV-TB patients were stimulated with an antigen of Mtb in the presence/absence of 7-OD at 1 × 10−6M or DHEA at 1 × 10−7M. Then, cells were
stained and analyzed by flow cytometry, as described before. This figure shows the percentage of CD4 + T cells that express (a) FoxP3, T-bet,
ROR-γt or CD25 and the co-expression of transcription factors using a Boolean gating strategy or (b) CD4+ Tregs and uTregs, with the co-
expression of the transcription factors ROR-γt or T-bet within each population. Values are relativized to unstimulated cells. The results are plotted
for HIV-TB patients. Each symbol represents an individual subject. Friedman test followed by post-hoc comparisons: Fisher’s LSD or Dunn’s test, as
appropriated *p < 0.05, **p < 0.01 and ***p < 0.005
Vecchione et al. Journal of Biomedical Science           (2020) 27:20 Page 19 of 23
Fig. 12 The equilibrium between Th1, Tregs, uTregs and Th17 subsets are disrupted by Mtb and modified by 7-OD and DHEA. Recently thawed
or freshly isolated PBMCs from HIV-TB individuals were stained and analyzed by flow cytometry, as indicated in methods. Figure shows CD4 + T
cell subset ratios. The results are plotted for HIV-TB patients (black circles) comparing (a) Control vs. stimulated cells. Unpaired t test or Mann-
Whitney U test, as appropriated *p < 0.05. (b) Distinct CD4+ Th subset ratios of Mtb-stimulated PBMCs treated with 7-OD and DHEA. Each symbol
represents an individual subject. Friedman test followed by post-hoc comparisons: Fisher’s LSD or Dunn’s test, as appropriated *p < 0.05,
**p < 0.01 and ***p < 0.005
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promoted a regulatory CD4 + T cell phenotype, 7-OD
expanded CD4 + T-bet+ subpopulation and enhanced T-
bet expression, which were related to improved clinical
outcomes. Furthermore, 7-OD decreased the percentage
of CD4 + T cells with immunosuppressive functions. Fi-
nally, 7-OD increased Th1/regulatory ratio, indicating
the predominance of a Th1 response which may contrib-
ute to TB protection by secreting IFN-γ and activating
anti-mycobacterial mechanisms. These results provide
new data to delineate novel strategies that accompany
the treatment of TB, by modulating T cell-mediated im-
munity against Mycobacterium tuberculosis.
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1186/s12929-019-0604-z.
Additional file 1: Figure S1. A representative analysis of the gating
strategy developed during this study. Recently thawed or freshly isolated
PBMCs were stained and analyzed by flow cytometry. The results are
plotted for a sample from a HD labelled with (A) fluorochrome-conjugated
Abs or (B) isotype control mAbs. Lymphocyte subset data were generated
using a FSC-A/SSC-A gate. After doublet exclusion (FSC-A/FSC-H and FSC-H/
FSC-W), live cells were selected using Live/Dead viability probe. Then, CD3 +
CD4+ cells were gated and within this group, a gating on CD25+, FoxP3+,
ROR-γt + or T-bet+ was done. CD4 + T cells that expressed one or two tran-
scription factors were evaluated using Boolean combination gates. Repre-
sentative flow cytometry examples are shown
Additional file 2: Figure S2. CD4+ T-cell phenotype is modified by
Mtb. Recently thawed or freshly isolated PBMCs from HD were stimulated
with Mtb, stained and analyzed by flow cytometry, as indicated in methods.
Figure shows the percentage of CD4 + T cells that express (A) FoxP3, T-bet,
ROR-γt or CD25 and (B) the co-expression of transcription factors using a
Boolean gating strategy. (C) Tregs (CD4 + CD25 + FoxP3+) and uTregs
(CD4 + CD25-FoxP3+) subsets were also analyzed. Representative flow cy-
tometry examples are shown. Each symbol represents an individual subject.
Unpaired t test or Mann-Whitney U test, as appropriated *p < 0.05, **p <
0.01 and ***p < 0.005
Additional file 3: Figure S3. Mtb-specific response in HD is modulated
by 7-OD and DHEA. Recently thawed or freshly isolated PBMCs from HD
were stimulated with Mtb in the presence/absence of 7-OD at 1 × 10−6M
or DHEA at 1 × 10−7M. Then, cells were stained and analyzed by flow cy-
tometry, as described before. Figure shows the percentage of CD4 + T
cells expressing (A) FoxP3, T-bet, ROR-γt or CD25 and the co-expression
of transcription factors using a Boolean gating strategy or (B) CD4+ Tregs
and uTregs, with the co-expression of the transcription factors ROR-γt or
T-bet within each population. Values are relativized to unstimulated cells.
The results are plotted for HD. Each symbol represents an individual sub-
ject. Friedman test followed by post-hoc comparisons: Fisher’s or Dunn’s
test, as appropriated *p < 0.05, **p < 0.01 and ***p < 0.005
Additional file 4: Figure S4. The equilibrium between Th1, Tregs,
uTregs and Th17 subsets are disrupted by Mtb and modified by 7-OD
and DHEA. Recently thawed or freshly isolated PBMCs from HD individ-
uals were stained and analyzed by flow cytometry, as indicated in
methods. Figure shows CD4 + T cell subset ratios. The results are plotted
for HD (open circles) comparing (A) Control vs. stimulated cells. Unpaired
t test (normal distribution) or Mann-Whitney U test (non-normal variables)
*p < 0.05. (B) Distinct CD4+ Th subset ratios of Mtb-stimulated PBMCs
treated with 7-OD and DHEA. Each symbol represents an individual sub-
ject. Friedman test followed by post-hoc comparisons: Fisher’s LSD or
Dunn’s test, as appropriated *p < 0.05, **p < 0.01 and ***p < 0.005
Additional file 5: Table S1. Expression of FoxP3, T-bet, ROR-γt and
CD25 on a per cell basis in CD4 + T lymphocytes from HIV-TB patients.
Recently thawed or freshly isolated PBMCs from HIV-TB were stimulated
with Mtb in the presence/absence of 7-OD at 1 × 10−6M or DHEA at 1 ×
10−7M. Then, cells were stained and analyzed by flow cytometry, as de-
scribed before. Table shows median fluorescence intensity (MFI), which
was calculated as the ratio of the geometric mean MFI of the marker of
interest over MFI of the corresponding negative population. MFI is
expressed as median ± interquartile range (IQR). Friedman test followed
by Fisher’s LSD or by Dunn’s test, as appropriate *p < 0.05, **p < 0.01 and
***p < 0.005. * indicates significant differences with Mtb-stimulated cells
(Mtb)
Abbreviations
7-OD: 7-oxo-dehydroepiandrosterone, 7-oxo-DHEA; AET: Androstenetriol;
Ag: Antigen; Anti-TB: Antituberculosis treatment; CPM: Counts per minute;
DHEA: Dehydroepiandrosterone; HAART: Highly active antiretroviral therapy;
HD: Healthy donors; HDT: Host-directed therapies; HIV: Human
immunodeficiency virus; HIV-TB: HIV-Mtb coinfected patients or HIV-Mtb
coinfection; IRIS: Immune Reconstitution Inflammatory Syndrome; MFI: Mean
fluorescence intensity; Mtb: Mycobacterium tuberculosis; PBMCs: Peripheral
blood mononuclear cells; SEM: Standard error of the mean; TB: Tuberculosis;
TF: Transcription factor; Tregs: Conventional regulatory CD4 + T cells (i.e.,
CD25 + FoxP3); TST: Tuberculin skin test; uTregs: Unconventional regulatory
CD4 + T cells (i.e., CD25-FoxP3+)
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